

References QBRI Insights: COVID-19 Vaccination - To boost or not to boost

1. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet Lond. Engl.* 2020, 395, 497–506, doi:10.1016/S0140-6736(20)30183-5.
2. WHO Coronavirus (COVID-19) Dashboard Available online: <https://covid19.who.int> (accessed on 16 December 2021).
3. QBRI Insights: COVID-19 Vaccine and Treatment Updates Available online: <https://www.hbku.edu.qa/en/news/vaccine-treatment-updates> (accessed on 16 December 2021).
4. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death | Pfizer Available online: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results> (accessed on 16 December 2021).
5. COVID-19 Vaccine Tracker and Landscape Available online: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines> (accessed on 16 December 2021).
6. Qatar: The Latest Coronavirus Counts, Charts and Maps. Reuters.
7. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* 2021, 384, 403–416, doi:10.1056/NEJMoa2035389.
8. Thomas, S.J.; Moreira, E.D.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Polack, F.P.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N. Engl. J. Med.* 2021, 0, null, doi:10.1056/NEJMoa2110345.
9. Self, W.H. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. *MMWR Morb. Mortal. Wkly. Rep.* 2021, 70, doi:10.15585/mmwr.mm7038e1.
10. Feikin, D.; Higdon, M.M.; Abu-Raddad, L.J.; Andrews, N.; Araos, R.; Goldberg, Y.; Groome, M.; Huppert, A.; O'Brien, K.; Smith, P.G.; et al. Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression.
11. Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N. Engl. J. Med.* 2021, 0, null, doi:10.1056/NEJMoa2114114.

12. Falsey, A.R.; Frenck, R.W.; Walsh, E.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Bailey, R.; Swanson, K.A.; Xu, X.; et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N. Engl. J. Med.* 2021, 0, null, doi:10.1056/NEJMc2113468.
13. Tracking SARS-CoV-2 Variants Available online: <https://www.who.int/emergencies/what-we-do/tracking-SARS-CoV-2-variants> (accessed on 16 December 2021).
14. Pfizer and BioNTech Provide Update on Omicron Variant | Pfizer Available online: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant> (accessed on 16 December 2021).